Building on this finding and on accumulating evidence of a presymptomatic phase of ALS characterized by early NfL elevation prior to clinical onset [153], the ATLAS trial is now investigating Tofersen as a preventive intervention in asymptomatic SOD1 mutation carriers, using NfL as a pharmacodynamic marker [154]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.